Vimarsana
Biggest News Aggregation in the World

Page 6 - Study Evaluating News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Study Evaluating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Study Evaluating Today - Breaking & Trending Today

Study: RenalGuard Not Superior in Avoiding CIN in High-Risk Cases - Vimarsana News

Study: RenalGuard Not Superior in Avoiding CIN in High-Risk Cases

A randomized controlled trial showed that RenalGuard is no better than conventional IV hydration at preventing contrast-induced nephropathy in high-risk patients.

Best Gluten-Free Protein Powder [2022 Updated] - Vimarsana News

Best Gluten-Free Protein Powder [2022 Updated]

Gluten can be a nightmare for people who have digestive problems or are gluten intolerant. Here are 2023 best gluten-free protein powders.

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years - Vimarsana News

New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with...

FDA Issues Guidance On Expansion Cohorts In Clinical Trials Of Oncology Drugs - Vimarsana News

FDA Issues Guidance On Expansion Cohorts In Clinical Trials Of Oncology Drugs

The FDA issued the final guidance document for first-in-human trial designs that consist of both dose escalation as well as multiple expansion...

Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology - Vimarsana News

Osivax Announces Publication of Phase 2a Trial Results for Influenza Vaccine Candidate OVX836 in Frontiers in Immunology

Data also discussed in context of OVX836 clinical development update presentation at 2022 World Vaccine Congress Osivax, a biopharmaceutical company developing vaccines to protect against highly